Grazie di avere visitato il nostro sito Internet.
Questo sito è riservato ai professionisti sanitari.

Une professionnelle de santé en train de travailler

Je suis un·e professionnel·le de santé

Un patient est au téléphone

Je souhaite accéder au site "patient"

Nomina di Cyrille Fleury CEO del Gruppo MENIX

Cyrille Fleury has been appointed Chief Executive Officer of Menix Group, specialized in Orthopaedic and Dental implants. He brings more than 15 years of experience in the medical device and digital technology industry.

MENIX Group is a fast-growing specialist designer, manufacturer and distributor of orthopaedic (primarily hip and knee) and dental implants, as well as 3D digital solutions. In less than 10 years, the group has multiplied its turnover by 10 reaching € 84 million in 2020, has 450 employees and continues to record double-digit year-over-year growth.

« I am pleased to welcome Cyrille as our CEO. He has a proven track record within the medical device industry, and he brings a very strong expertise and knowledge of international markets. I have been impressed by his leadership and vision, and I look forward to have him driving MENIX to the next level of

success » commented Patrick Rondot, President of MENIX Group.

 

Cyrille graduated with a Biomedical Engineering degree from Université Technologique de Compiègne (France) and a Master of Engineering from McGill University (Canada). He also holds a Management Certificate from INSEAD Business School (France). He has more than 15 years of experience in the medical device and digital technology

industry.

More recently, Cyrille was Country Manager for Wright Medical Group in France, focused on Extremities & Biologics, following the merger between Tornier and Wright. Prior to Wright Medical, Cyrille held several managerial positions at Tornier, in the Larges Bones and Upper Business Units, and contributed to the launch of the Tornier UK subsidiary. He is also Vice-President of the orthopaedic group and Board Member of the Syndicat des Technologies Médicales (SNITEM).

As CEO, Cyrille Fleury will be based in Lyon near the corporate headquarter. He plans on strengthening the product portfolio and on increasing the Group’s international presence.

« I am delighted to join MENIX, a company with unique products focused on innovative concepts associated to 3D digital technology with and for the surgeons. I am especially excited to work with the Menix team to increase the geographical footprint while reinforcing the product portfolio, to drive the business forward into its next exciting chapter. » added Cyrille Fleury, CEO of MENIX Group.

« MENIX has demonstrated medical credibility and the superiority of its products in its core markets. With Cyrille’s appointment as CEO, we are looking forward to expanding its leadership beyond Its current core areas of focus in the hip and dental markets » said Victor Decrion, Partner at Five Arrows Principal Investments part of Rothschild & Co Group.

Presse Contacts – Amalthea Agency

Coradine Sersiron – csersiron@amalthea.fr
Fabienne Boccard – fboccard@amalthea.fr

Read more in our press release

 

About MENIX Group,

MENIX Group is a fast-growing specialist designer, manufacturer and distributor of orthopaedic (primarily hip and knee) and dental implants, as well as 3D digital solutions. In the orthopaedic business, MENIX Group enjoys a leading position in the dual mobility market in France. Dual mobility cups, which the company invented 30 years ago, significantly reduce risks of luxation of hip prostheses and are being increasingly used worldwide. On the dental side, MENIX Group designs and markets a successful range of dental implants and implantable devices used in cranio-maxillo-facial surgery. The company has reached € 84 million and 450 employees in 2020 and is headquartered close to Lyon, France.

 

About Five Arrows Principal,

Five Arrows Principal Investments (FAPI) is the European private equity arm of Rothschild & Co’s Merchant Banking business. Merchant Banking manages over €15bn globally which includes approximately €3.4 billion dedicated to corporate private equity, as well as a series of funds dedicated to senior and junior credits, primary and secondary fund investing and coinvestments, with offices in Paris, London, New York, Los Angeles and Luxembourg. FAPI is focused on investing in middle-market companies with highly defensible market positions; strong management teams; business models with high visibility of organic unit volume growth and strong free cash flow conversion; and multiple operational levers that can be used to unlock latent value. Sectors are limited to data and software, technology-enabled business services and healthcare.

 

About Keensight Capital

Keensight Capital, one of the leading European Growth Buyout firms, is committed to supporting entrepreneurs as they implement their growth strategies. For 20 years, Keensight Capital’s team of seasoned professionals has leveraged their knowledge of investment and growth industries to invest for the long term in profitable companies with high growth potential and revenues in the range of €15 million to €250 million.

Drawing on its expertise in the Information Technology/Internet and Healthcare/Wellbeing sectors, Keensight identifies the best investment opportunities in Europe and works closely with management teams to develop and achieve their strategic vision.

 

About Turenne Capital

Turenne Group is a French major player in Private Equity, supporting entrepreneurs in their business development and transferring for 20 years. Turenne Capital is an independent firm owned by its management, with €1 billion in assets under management. Its teams support 250 businesses, in health sector, hotel industries, new technologies, distribution or innovative services. Turenne Group has built up a proven track record in the following key investment fields: healthcare, hotels, innovative industry, ecotechnology, specialised retail, services and IT services.

Succedding Together